medigraphic.com
ISSN 1561-3054 (Electronic)

2012, Number 2

<< Back Next >>

Rev Cubana Med Trop 2012; 64 (2)

Response to therapy in multiple drug resistant tuberculosis patients

García DMP, García SE, Solano LM, Milanés VMT

Language: Spanish
References: 19
Page:
PDF size: 56.80 Kb.


ABSTRACT

Introduction: multiple drug resistant tuberculosis is an increasingly significant medical problem, because it means the spread of microorganisms for which "second line" drugs are required to eliminate them; therapeutic effectiveness is lower, it takes longer to treat it, leading to more adverse effects in addition to being more expensive than the conventional treatment.
Objective: to identify the response to individualized treatment in multiple drug resistant tuberculosis patients, who are non-HIV seropositive.
Method: a descriptive study was conducted in a sample of multiple drug resistant patients, who were treated for a year under individualized courses of treatment from 2000 to 2010 in Hospital Neumológico "Benéfico Jurídico". Data were collected from their medical histories and from bacteriological records.
Results: out of 42 patients, 85.7 % were males and the average age was 48.8 years. The most common category on admission was chronically-ill patient (40.5 %). The average time for negative results in direct exam was 4.6 months and in culturing was 6 months; this indicator was lower in patients regarded as failures and higher in those classified as relapses. The highest healing percentage was found in chronic patients and in those classified as failures, accounting for 23.8 and 21.4 % respectively.
Conclusions: the compliance with individualized treatment under direct observation in multiple drug resistant tuberculosis proved to be effective in over half of the cases.


REFERENCES

  1. WHO. Global tuberculosis control: surveillance, planning, financing. WHO report 2009. WHO/HTM/TB/2009.340. Geneva: World Health Organization; 2005.

  2. Global Tuberculosis Control: Surveillance, Planning, Financing. WHO Report. Geneva: World Health Organization; 2006. WHO/HTM/TB/2006. 362.

  3. Ministerio de Salud Pública (MINSAP). Anuario Estadístico de Salud. La Habana: MINSAP, Dirección Nacional de Estadística; 2010.

  4. Anti-tuberculosis drug resistance in the world: The WHO/IUATLD global project on antituberculosis drug resistance surveillance 2002-2007. WHO/TB/07394. Geneva: World Health Organization; 2008.

  5. Palmero DJ, Laniado R, Caminero JA. Guías latinoamericanas de diagnóstico y tratamiento de la tuberculosis farmacorresistente. Arch Bronconeumol. 2008;44(10):578-80.

  6. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Geneva: World Health Organization; 2010. WHO/HTM/TB/2010.3.

  7. Montoro CE. Multiple drug resistance: a threat for tuberculosis control. Rev Panam Salud Publica. 2004;(16):1:68.

  8. Machado D. Robert Koch, el Hospital Neumológico "Benéfico Jurídico" y la tuberculosis en Cuba. Rev Cubana Hig Epidemiol [serie en Internet]. 2004 Dic [citado 2011 Ene 13];42(3). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-30032004000300008&lng=es

  9. Brodie D, Schluger NW. The diagnosis of Tuberculosis. Clin Chest Med. 2005;26:247-71.

  10. Glikman SW, Rasiel EB, Hamilton CD, Kubataev A, Shylman KA. A portfolio model of drug development for tuberculosis. Science. 2006;311:1246-7.

  11. Espinal MA. Epidemiology of multidrug-resistant tuberculosis in low- and middle-income countries. In: Bastian I, Portaels F, editors. Multidrug-resistant tuberculosis. London: Kluwer Academic Publishers; 2000. p. 35-48.

  12. World Health Organization Stop TB Department. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. WHO/HTM/TB/2008.402. Geneva, Switezerland: WHO; 2008.

  13. Lienhardt C, Davies G. Methodological issues in the design of clinical trials for the treatment of multidrug-resistant tuberculosis: challenges and opportunities. Int J Tuberc Dis. 2010;14(5):528-37.

  14. 14.Park SK, Lee WC, Lee DH, Mitnick CD, Han L, Seung KJ. Self- administered, standardized regimens for multidrugresistant tuberculosis in South Korea . Int J Tuberc Lung Dis. 2004;8(3):361-8.

  15. Martínez D, Torres A, Villarreal H, Báez R, Salazar MA. Resultado de retratamiento estandarizado en pacientes con tuberculosis resistente a múltiples fármacos (TB-MDR).Instituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas". México 2003-2005. Neumología y Cirugía de Tórax. 2009;6(1):7-16.

  16. Rustomjee R, Lienhardt C, Kanyok T, Davies R, Levin J, Mthiyane T. Study of the sterilizing activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2008;12:128-38.

  17. Tahaoglu K, Torun T, Sevim T, Atac G, Kir A, Karasulu L, et al. The treatment of multidrug-resistant tuberculosis in Turkey. New Engl J Med. 2001;345:170-4.

  18. Holtz T, Sternberg M, Kammerer S, Laserson KF, Riekstina V, Zarovska E Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann Intern Med. 2006;144.650-9.

  19. Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and metanalysis. Lancet Infect Dis. 2009;9:153-61.




2020     |     www.medigraphic.com